AR039352A1 - Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5. - Google Patents
Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5.Info
- Publication number
- AR039352A1 AR039352A1 ARP020101765A ARP020101765A AR039352A1 AR 039352 A1 AR039352 A1 AR 039352A1 AR P020101765 A ARP020101765 A AR P020101765A AR P020101765 A ARP020101765 A AR P020101765A AR 039352 A1 AR039352 A1 AR 039352A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- seq
- compound
- inhibitors
- igs5
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Uso de un compuesto que tiene actividad inhibidora combinada y en particular concurrente de endopeptidasa neutra (NEP) y una novedosa metaloproteasa denominada IGS5, que es un polipéptido que comprende una secuencia de aminoácidos que tiene una identidad de al menos 70% con relación a una de las secuencias de aminoácidos elegidas del grupo de SEQ ID NO: 2, SEQ ID NO: 4 y SEQ ID NO: 6; o una sal o solvato o éster biolábil farmacéuticamente aceptable del mismo, para la preparación de un medicamento o composición farmacéutica para tratar mamíferos superiores y preferiblemente seres humanos que sufren de o son susceptibles a una enfermedad o condición que puede ser aliviada o impedida por inhibición combinada o concurrente de IGS5. Además la presente se refiere a una composición farmacéutica que comprende cantidades co-eficaces y preferiblemente sinérgicamente eficaces de un primer compuesto que tiene actividad inhibidora combinada o concurrente de NEP/IGS5, preferiblemente derivados de ácido benzazepin-n-acético sustituido de la fórmula (1) o una sal, solvato o éster biolábil farmacéuticamente aceptable del mismo, y al menos un compuesto adicional elegido del grupo de otros inhibidores de metalopoteasa individuales y/o combinantes, estando elegido preferiblemente dicho compuesto del grupo que comprende los inhibidores de ACE, inhibidores selectivos de ECE, inhibidores selectivos de NEP, inhibidores duales de NEP/ECE, inhibidores mixtos de estas metaloproteasas. Reivindicación 10: Uso de un compuesto de la fórmula (1), en la cual: A representa un grupo con las fórmulas (2) o (3), en cuya fórmula (2) R1a representa un grupo fenil-(alquilo inferior), opcionalmente sustituido en el ciclo fenilo por alquilo inferior, alcoxi inferior o halógeno o un grupo naftil-(alquilo inferior), R2a representan hidrógeno o un grupo que forma un éster biolábil y en cuya fórmula (3) R1b representa hidrógeno o un grupo que forma un éster de ácido fosfónico biolábil, R2b es hidrógeno o un grupo que forma un éster de ácido fosfónico biolábil, y en donde R3 representa hidrógeno o un grupo que forma un éster de ácido carboxílico biolábil, o una sal o solvato o éster biolábil farmacéuticamente aceptable del mismo para la preparación de un medicamento o composición farmacéutica para tratar mamíferos superiores, preferiblemente seres humanos, que sufren de o son susceptibles a una enfermedad o condición que puede ser aliviada o impedida por inhibición combinada o concurrente de: a) endopeptidasa neutra (NEP) y b) metaloproteasa IGS5 que es un polipéptido que comprende una secuencia de aminoácidos que tiene una identidad de a menos 70% con relación a una de las secuencias de aminoácidos elegida del grupo que comprende SEQ ID NO: 2, SEQ ID NO: 4, y SEQ ID NO: 6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112231 | 2001-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039352A1 true AR039352A1 (es) | 2005-02-16 |
Family
ID=32842671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101765A AR039352A1 (es) | 2001-05-18 | 2002-05-14 | Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040162345A1 (es) |
| EP (1) | EP1397141A2 (es) |
| JP (1) | JP2004536063A (es) |
| CN (1) | CN1520299A (es) |
| AR (1) | AR039352A1 (es) |
| BR (1) | BR0209855A (es) |
| CA (1) | CA2447598A1 (es) |
| CZ (1) | CZ20033183A3 (es) |
| HU (1) | HUP0400988A3 (es) |
| MX (1) | MXPA03010341A (es) |
| PL (1) | PL367093A1 (es) |
| RU (1) | RU2003136077A (es) |
| SK (1) | SK14102003A3 (es) |
| WO (1) | WO2002094176A2 (es) |
| ZA (1) | ZA200308098B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2392076A1 (en) | 1999-11-19 | 2001-05-25 | Solvay Pharmaceuticals B.V. | Human enzymes of the metalloprotease family |
| WO2004010106A2 (en) * | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
| US7452875B2 (en) | 2003-09-26 | 2008-11-18 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7262184B2 (en) | 2003-09-26 | 2007-08-28 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7427611B2 (en) | 2003-09-26 | 2008-09-23 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| WO2005067937A1 (en) * | 2004-01-12 | 2005-07-28 | Solvay Pharmaceuticals B.V. | Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders |
| US7232813B2 (en) | 2004-01-12 | 2007-06-19 | Solvay Pharmaceuticals B.V. | Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders |
| US20050267072A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction |
| US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
| WO2005112939A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Medicaments containing dually acting inhibitors of neutral endopeptidase and of human soluble endopeptidase for the treatment of sexual dysfunction |
| WO2006000564A1 (en) * | 2004-06-23 | 2006-01-05 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists |
| US20050288272A1 (en) * | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
| EP1827448A1 (en) | 2004-12-15 | 2007-09-05 | Solvay Pharmaceuticals GmbH | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors |
| BRPI0608184A2 (pt) * | 2005-02-18 | 2009-11-17 | Solvay Pharm Gmbh | composições farmacêuticas compreendendo inibidores da nep, inibidores da nep, inibidores do sistema de produção de endotelina endógena e diuréticos |
| US20060205625A1 (en) * | 2005-02-18 | 2006-09-14 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
| KR101970505B1 (ko) | 2012-12-26 | 2019-04-19 | (주)아모레퍼시픽 | 멜라닌 형성 억제제를 함유하는 미백용 피부 외용제 조성물 |
| MA41553B1 (fr) | 2015-02-16 | 2020-04-30 | The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv | Sulfonylurées, composés apparentés, et leur utilisation |
| TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
| US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| DK3661925T3 (da) | 2017-07-07 | 2022-02-28 | Inflazome Ltd | Hidtil ukendte sulfonamidcarboxamidforbindelser |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| TW201910314A (zh) * | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| RU2020110219A (ru) | 2017-08-15 | 2021-09-17 | Инфлазоум Лимитед | Сульфонилмочевины и сульфонилтиомочевины в качестве ингибиторов nlrp3 |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| PL424452A1 (pl) * | 2018-01-31 | 2019-08-12 | Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR880007441A (ko) * | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
| EP0785273A1 (en) * | 1990-11-26 | 1997-07-23 | Genetics Institute, Inc. | Paired basic amino acid converting enzyme and DNA sequence encoding it |
| DE19510566A1 (de) * | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
| DE19750002A1 (de) * | 1997-11-12 | 1999-05-20 | Solvay Pharm Gmbh | Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US20020086405A1 (en) * | 2000-09-25 | 2002-07-04 | Inmaculada Silos-Santiago | 56638, a novel human neprilysin protease and uses thereof |
| DE19906310A1 (de) * | 1999-02-16 | 2000-08-17 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von Bluthochdruck |
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| JP2001275687A (ja) * | 2000-04-04 | 2001-10-09 | Masafumi Matsuo | 膜結合型メタロプロテアーゼ及びその可溶性分泌型 |
| GB0017387D0 (en) * | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
| US6991916B2 (en) * | 2000-07-14 | 2006-01-31 | Pfizer Inc. | Compounds for the treatment of sexual dysfunction |
| US20030119714A1 (en) * | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
-
2002
- 2002-05-14 PL PL02367093A patent/PL367093A1/xx not_active Application Discontinuation
- 2002-05-14 RU RU2003136077/15A patent/RU2003136077A/ru not_active Application Discontinuation
- 2002-05-14 WO PCT/EP2002/005259 patent/WO2002094176A2/en not_active Application Discontinuation
- 2002-05-14 CZ CZ20033183A patent/CZ20033183A3/cs unknown
- 2002-05-14 SK SK1410-2003A patent/SK14102003A3/sk unknown
- 2002-05-14 BR BR0209855-5A patent/BR0209855A/pt not_active IP Right Cessation
- 2002-05-14 MX MXPA03010341A patent/MXPA03010341A/es not_active Application Discontinuation
- 2002-05-14 JP JP2002590897A patent/JP2004536063A/ja not_active Withdrawn
- 2002-05-14 CA CA002447598A patent/CA2447598A1/en not_active Abandoned
- 2002-05-14 CN CNA028101545A patent/CN1520299A/zh active Pending
- 2002-05-14 AR ARP020101765A patent/AR039352A1/es not_active Application Discontinuation
- 2002-05-14 EP EP02743004A patent/EP1397141A2/en not_active Withdrawn
- 2002-05-14 HU HU0400988A patent/HUP0400988A3/hu unknown
-
2003
- 2003-10-17 ZA ZA200308098A patent/ZA200308098B/en unknown
- 2003-11-18 US US10/715,112 patent/US20040162345A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002094176A3 (en) | 2003-12-11 |
| JP2004536063A (ja) | 2004-12-02 |
| SK14102003A3 (sk) | 2004-08-03 |
| US20040162345A1 (en) | 2004-08-19 |
| WO2002094176A2 (en) | 2002-11-28 |
| CA2447598A1 (en) | 2002-11-28 |
| ZA200308098B (en) | 2004-10-18 |
| HUP0400988A3 (en) | 2006-07-28 |
| EP1397141A2 (en) | 2004-03-17 |
| HUP0400988A2 (hu) | 2004-08-30 |
| BR0209855A (pt) | 2004-06-15 |
| MXPA03010341A (es) | 2004-03-10 |
| PL367093A1 (en) | 2005-02-21 |
| RU2003136077A (ru) | 2005-08-10 |
| CZ20033183A3 (cs) | 2004-07-14 |
| CN1520299A (zh) | 2004-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039352A1 (es) | Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5. | |
| ATE349463T1 (de) | Verbrückte bizyklische serinproteaseinhibitoren | |
| ATE539744T1 (de) | Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem | |
| DK1615613T3 (da) | Quinoxalinyl-makrocykliske hepatitis C serin protease-inhibitorer | |
| WO2006039488A3 (en) | Hcv ns3-ns4a protease inhibition | |
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| MY148123A (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| WO2008106058A3 (en) | Inhibitors of serine proteases | |
| UY30437A1 (es) | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c | |
| HK1101402A1 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| AR036101A1 (es) | Derivados naftil indol sustituidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento como inhibidores del inhibidor de tipo -1 activador de plasminogeno (pai-1) | |
| MX2010006210A (es) | Inhibidores de serina proteasa de hcv de tripeptido fluorado. | |
| BRPI0407922A (pt) | derivados de isoquinolina e métodos de uso destes | |
| UY30392A1 (es) | Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c | |
| NO20060706L (no) | Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease | |
| EA200000871A1 (ru) | Ингибиторы фосфолипазных ферментов | |
| WO2003087092A3 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease | |
| WO2009053828A3 (en) | P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors | |
| WO2008021956A3 (en) | Acylaminoheteroaryl hepatitis c virus protease inhibitors | |
| EA200100971A1 (ru) | Новые соединения и композиции в качестве ингибиторов протеазы | |
| MY155851A (en) | Quinoxaline-containing compounds as hepatitis c virus inhibitors | |
| AR027533A1 (es) | Derivados de acido malonico, procesos para su preparacion, su uso y composiciones farmaceuticas que los contienen | |
| RS52945B (en) | PHARMACEUTICAL FORMULATIONS AND THEIR APPLICATION IN THE TREATMENT OF WOMEN SEXUAL DYSFUNCTION | |
| PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
| AR054550A1 (es) | Metodos para tratar la epileptogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |